NO20062371L - Hittil ukjente krystallinske former av {2-[1-(3,5-bis-trifluormetyl-benzyl)-5-pyridin-4-yl-1 H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon - Google Patents

Hittil ukjente krystallinske former av {2-[1-(3,5-bis-trifluormetyl-benzyl)-5-pyridin-4-yl-1 H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon

Info

Publication number
NO20062371L
NO20062371L NO20062371A NO20062371A NO20062371L NO 20062371 L NO20062371 L NO 20062371L NO 20062371 A NO20062371 A NO 20062371A NO 20062371 A NO20062371 A NO 20062371A NO 20062371 L NO20062371 L NO 20062371L
Authority
NO
Norway
Prior art keywords
triazol
pyridin
methanone
chlorophenyl
trifluoromethyl
Prior art date
Application number
NO20062371A
Other languages
English (en)
Other versions
NO335090B1 (no
Inventor
Susan Marie Reutzel-Edens
David Scott Coffey
Steven Wayne Pedersen
Pamela Kaye Footman
Alfio Borghese
Shella Lenyonga Tameze
Carsten Weber
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20062371L publication Critical patent/NO20062371L/no
Publication of NO335090B1 publication Critical patent/NO335090B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Gjeldende oppfinnelse tilbyr hittil ukjente krystallinske former av {2-[l-(3,5-bistrifluormetylbenzyl)-5-pyridin-4-yl-lH-[l,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon, sammensetninger derav, mellomledd derav, metoder for å bruke det samme, fremgangsmåter for å bruke det samme og fremgangsmåter for å lage mellomledd derav.
NO20062371A 2003-10-24 2006-05-24 Nye krystallinske former av {2-[1-(3,5-bistrifluormetylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon, fremgangsmåter for fremstilling derav, og farmasøytiske sammensetninger som inneholder slike. NO335090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (2)

Publication Number Publication Date
NO20062371L true NO20062371L (no) 2006-05-24
NO335090B1 NO335090B1 (no) 2014-09-08

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062371A NO335090B1 (no) 2003-10-24 2006-05-24 Nye krystallinske former av {2-[1-(3,5-bistrifluormetylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon, fremgangsmåter for fremstilling derav, og farmasøytiske sammensetninger som inneholder slike.

Country Status (28)

Country Link
US (1) US7381826B2 (no)
JP (1) JP4959336B2 (no)
KR (1) KR100848407B1 (no)
CN (1) CN1863791B (no)
AR (1) AR046131A1 (no)
AT (1) ATE462700T1 (no)
AU (1) AU2004285855B8 (no)
BR (1) BRPI0415010B8 (no)
CA (1) CA2542140C (no)
CL (2) CL2009001310A1 (no)
CR (1) CR8353A (no)
DE (1) DE602004026333D1 (no)
DK (1) DK1675846T3 (no)
EA (1) EA008881B1 (no)
EC (1) ECSP066517A (no)
ES (1) ES2340772T3 (no)
HR (1) HRP20100207T1 (no)
IL (1) IL174926A0 (no)
MA (1) MA28329A1 (no)
MY (1) MY157375A (no)
NO (1) NO335090B1 (no)
NZ (2) NZ580480A (no)
PE (1) PE20050481A1 (no)
PT (1) PT1675846E (no)
TW (1) TW200524906A (no)
UA (1) UA82901C2 (no)
WO (1) WO2005042515A1 (no)
ZA (1) ZA200603234B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체

Also Published As

Publication number Publication date
MY157375A (en) 2016-06-15
HRP20100207T1 (hr) 2010-05-31
AU2004285855B8 (en) 2011-04-28
UA82901C2 (en) 2008-05-26
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
CA2542140C (en) 2012-05-29
NO335090B1 (no) 2014-09-08
CN1863791A (zh) 2006-11-15
PT1675846E (pt) 2010-04-20
ES2340772T3 (es) 2010-06-09
JP4959336B2 (ja) 2012-06-20
EA200600829A1 (ru) 2006-08-25
NZ580480A (en) 2010-02-26
AU2004285855B2 (en) 2010-12-23
CL2009001310A1 (es) 2009-12-04
BRPI0415010B8 (pt) 2021-05-25
DK1675846T3 (da) 2010-05-31
BRPI0415010A (pt) 2006-11-07
JP2007509143A (ja) 2007-04-12
BRPI0415010A8 (pt) 2018-05-08
CA2542140A1 (en) 2005-05-12
ZA200603234B (en) 2007-07-25
KR20060061388A (ko) 2006-06-07
ATE462700T1 (de) 2010-04-15
PE20050481A1 (es) 2005-09-20
US20070078166A1 (en) 2007-04-05
WO2005042515A1 (en) 2005-05-12
MA28329A1 (fr) 2006-12-01
IL174926A0 (en) 2006-08-20
CL2009001311A1 (es) 2009-10-02
NZ545917A (en) 2009-11-27
AR046131A1 (es) 2005-11-23
CR8353A (es) 2006-06-06
TW200524906A (en) 2005-08-01
KR100848407B1 (ko) 2008-07-28
BRPI0415010B1 (pt) 2019-07-09
CN1863791B (zh) 2011-12-07
EA008881B1 (ru) 2007-08-31
ECSP066517A (es) 2006-10-10
AU2004285855A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
NO20062371L (no) Hittil ukjente krystallinske former av {2-[1-(3,5-bis-trifluormetyl-benzyl)-5-pyridin-4-yl-1 H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon
NO20061528L (no) Polymrofe former av 3-(4-amino-1-okso-1,3dihydro-isoindol-2-yl)-piperidin-2,6-dion
ATE373655T1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol- derivate als factor xa inhibitoren
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
NO20053045L (no) Kinolyl-pyrrol-pyrazoler.
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
ATE391126T1 (de) Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols
NO20073366L (no) 1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose
NO20050650L (no) Fremgangsmate for selektiv fremstilling av aryl-5-tio- -D-aldoheksopyranosider
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
WO2003076398A3 (en) Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
HRP20050035B1 (hr) Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
EA200200100A1 (ru) Способ лечения или профилактики вазоспазма коронарного трансплантата
CY1110642T1 (el) Νεες κρυσταλλικες μορφες {2-[1-(3,5-δις-τριφθορομεθυλ-βενζυλ)-5-πυριδιν-4-υλ-1η-[1,2,3]τριαζολ-4-υλ]- πυριδιν-3-υλ}-(2-χλωροφαινυλ)-μεθανονης
HK1092475A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
ATE514678T1 (de) 2-substituierte heterocyclische verbindungen
NO20053431D0 (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
AU7667201A (en) Use of a vitamin combination for the treatment of primary headaches
MX2007003426A (es) Formas cristalinas de un inhibidor del factor xa, pirazolo-[3, 4-c]-piridina.
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
FI20001542A7 (fi) Menetelmä septisen sokin hoitamiseksi
NZ595125A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases